HC Wainwright & Co. Reiterates Buy on ProMIS Neurosciences, Maintains $18 Price Target
Benzinga Newsdesk 9 hours ago
Analyst RatingsNewsReiterationPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates ProMIS Neurosciences (NASDAQ:PMN) with a Buy and maintains $18 price target.
